TMEM203 and neoplasm: Since the HLA uLigand PTMEM203_B*07/C*16 (RSAGPRPAL) showed the highest frequency of tumor-specific presentation (8/45, 17.8%), we performed additional functional testing on the TMEM203 TLS (Fig. 4c).